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Introduction
The recently proposed revision of the Eighth Joint National
Committee (JNC-8) guideline on hypertension supported
by the American Heart Association (AHA), and the Amer-
ican College of Cardiology (ACC) [1], recommends a tar-
get systolic blood pressure (SBP) of 130 mm Hg or lower
for all hypertensive individuals. This requires a disruptive
practice change, by lowering the threshold SBP for initia-
tion of antihypertensive therapy by 10 to 20 mm Hg. The
recommendations of the guideline were heavily influenced
by the results of the SPRINT trial [2], which compared
a standard treatment group with a target SBP <140 mm
Hg with an intensive treatment group with a target SBP
of <120 mm Hg, in patients at high cardiovascular risk.
An SBP target of <120 mm Hg resulted in lower rates of
fatal and nonfatal major cardiovascular events and death
from any cause, but in significantly higher rates of some
adverse, when compared with an SBP target of <140 mm
Hg.
There are, however, are several characteristics of the
SPRINT trial that limit its external and internal validity.
First, in SPRINT blood pressure measurements were per-
formed using automated office equipment and made three
times unobserved. This is critically important because SBP
when measured this way may be 5 to 10 mm Hg lower
than when measured with a manual instrument, or when
patients are being observed or talking, or in a room that is
not quiet [3]. Second, the strict inclusion and exclusion cri-
teria mean thaat older persons with common diseases such
as stroke and diabetes, and geriatric syndromes such as de-
mentia and malnutrition were not included. Third, the tri-
al was stopped prematurely because of clear evidence of
benefit, and there is empirical evidence that trials stopped
early for benefit tend to overestimate the magnitude of the
treatment effect [4].
In line with this, the American Association of Family
Physicians (AAFP) has recently declined to endorse the
revised guideline [5]. Even though the American College
of Physicians (ACP) / AAFP blood pressure guideline has
itself been criticised for lacking author expertise [6], this
cannot be taken too seriously, as primary care physicians
are probably best equipped and positioned as generalists to
make an overall clinical judgment on the management of
hypertension in older adults and to practice the “first, do no
harm” principle.
So far, the debate has almost exclusively focused on lim-
itations in external validity of the SPRINT trial, whereas
its internal validity has not been criticised [7, 8]. Here,
we question SPRINT’s internal validity at three relevant
points.
Protocol violation of baseline systolic blood
pressure criterion in about a third of subjects
included in the SPRINT trial
About a third of the subjects in SPRINT did not have a
SBP ≥130 mm Hg at time of randomisation, but had a low-
er SBP at baseline (<125 mmHg), although this was an ex-
clusion criterion. The lowest tertile of the 9361 randomised
patients had a baseline SBP ≤132 mmHg [2]. This means
that a third of the patients in a trial looking at treatment of
older subjects with SBP between 130 and 180 mm Hg had
a SBP distributed within a 3 mm Hg range: between 130
and 132 mm Hg. This directly proves serious selection bias
towards the lower limit of the SBP inclusion criterion (i.e.,
130 mm Hg). This should have been recorded as a proto-
col violation, as the protocol clearly states that at randomi-
sation all inclusion and exclusion criteria should be ful-
filled. Probably, the SBP below the cut-off of 130 mm Hg
in the intensive and standard treatment groups was caused
by the first part of regression to the mean, from screening
to the baseline blood pressure measurement at randomi-
sation. The very purpose of the randomisation visit after
screening was to confirm the absence of a regression to the
mean in the blood pressure. In reality, such regression was
present, and thus we do not have evidence for valid SBP
criteria that defined start of treatment.
Can stopping antihypertensive drugs in hyper-
tensive patients inform a guideline to initiate
antihypertensive drug treatment?
The so called standard treatment group in SPRINT did not
reflect standard clinical practice in a large group of par-
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ticipants. More than a third of participants in this group
had a baseline SBP of <132 mm Hg. Therefore, in order to
achieve “a target goal of less than 140 mm Hg”, antihyper-
tensive drugs had to be stopped or reduced. This interven-
tion is completely different from initiating antihyperten-
sive drugs in treatment-naïve hypertensive individuals. It
comes as no surprise that the lowest SBP tertile in the stan-
dard treatment group experienced an increase in SBP to
reach a target blood pressure <140 mm Hg. This increase
was caused by a per protocol step-down procedure, con-
sisting of a dose reduction or reduction in number of anti-
hypertensive drugs. This step-down procedure was started
directly at the randomisation visit in many of these pa-
tients on standard treatment. As was recently shown in a
systematic review, withdrawal of hypertensive agents fre-
quently leads to adverse effects such as changes in bio-
chemistry, heart rate, pulse rate and kidney function and re-
bound hypertension in a larger proportion of patients [9].
Moreover, in patients with elevated cardiovascular risk, as
in SPRINT, this might also lead to a serious increase in
primary outcomes through a rebound effect in the standard
treatment group. This increase in risks by reduction of an-
tihypertensive therapy and lessening of beneficial lifestyle
adherence may have distorted the beneficial effect, which
in SPRINT is completely attributed to the beneficial effect
of intensive blood pressure control.
Interestingly, hazard ratios (HRs) for the comparison of
intensive with standard treatment for SPRINT’s primary
outcome (a composite outcome of myocardial infarction,
other coronary syndromes, stroke, heart failure or death
from cardiovascular causes) were lower in the lowest ter-
tile of baseline SBP (HR 0.7; 95% confidence interval
[CI] 0.51–0.95) than in the middle (HR 0.77; 95% CI
0.57–1.03) and the highest tertile (HR 0.83; 95% CI
0.63–1.09) of baseline blood pressure. This is in contradic-
tion to the fact that lowering blood pressure provided high-
est relative protection at the higher baseline SBP levels in
a recent meta-analysis including 74 trials with more than
300,000 individuals [10]. Assuming balanced baseline car-
diovascular risk in all tertiles of baseline SBP, larger dif-
ferences in risk reduction between intensive ad standard
treatment groups in individuals with lower baseline SBP
may reflect an increase in adverse effects due to a surge in
SBP in the standard treatment rather than a beneficial ef-
fect of more aggressive treatment in the intensive treatment
group.
Was the observed effectiveness in SPRINT
caused by intensified antihypertensive drugs
alone or by a more complex multifactorial an-
tihypertensive treatment?
Last but not least, the SPRINT trial was an open-label
study in older subjects in whom SBP reduction is usually
hard to achieve when they have age-related high blood
pressure, mediated by atherosclerosis and increased pe-
ripheral vascular resistance. The lifestyle changes in
SPRINT were coordinated by a Lifestyle and Background
Therapy Working Group, which actively spread materials
supporting medical nutrition therapy, weight management,
physical activity, smoking cessation and antithrombotic
therapy. However, SPRINT publications so far have not
reported the within- or the between-group changes in ad-
herence to a more healthy lifestyle, though they were part
of SPRINT in both arms. A SBP <120 mm Hg within 3
months after start, as was realized on average in the lowest
tertile, probably an important boost to continue a healthi-
er lifestyle. In the standard treatment the message of “your
SBP is too low” or “your SBP is falling quickly”, leading
per protocol to a step-down of drug treatment, is also likely
to affect the lifestyle behaviour of the subjects in the stan-
dard treatment group, but now in the opposite direction of
liberalisation (e.g. increased salt intake). Though the net
trial effects are the combination of a very complex com-
bined open-label intervention of antihypertensive drugs
and lifestyle, they are now completely attributed to the
drugs. This does not comply with the trial design and
analysis required for complex interventions [11].
Conclusion
The SPRINT trial’s serious problems in internal and ex-
ternal validity require great caution in implementing the
new US blood pressure guideline. Therefore, we propose
to at least temporarily make a step backwards to the safer,
more evidence-based, and more attainable general JNC-8
treatment goals, which advise initiation of treatment when
the blood pressure is 150/90 mm Hg or higher in adults
60 years or older, or 140/90 mm Hg or higher in adults
younger than 60 years. The new European Society of Car-
diology / European Society of Hypertension blood pressure
guideline is expected to be published in June 2018. Hope-
fully, it will be more thoughtful and patient-oriented than
the ACC/AHA guideline.
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